Last Price
0.59
Today's Change
+0.21 (55.26%)
Day's Change
0.481 - 0.67
Trading Volume
103,742,560
Overview
Market Cap
2 Million
Shares Outstanding
3 Million
Avg Volume
1,534,233
Avg Price (50 Days)
0.60
Avg Price (200 Days)
0.66
PE Ratio
-0.48
EPS
-1.23
Earnings Announcement
07-Apr-2025
Previous Close
0.38
Open
0.55
Day's Range
0.4814 - 0.6695
Year Range
0.365 - 1.52
Trading Volume
103,742,560
Price Change Highlight
1 Day Change
55.26%
5 Day Change
47.50%
1 Month Change
-1.58%
3 Month Change
15.57%
6 Month Change
-22.32%
Ytd Change
-4.84%
1 Year Change
-40.40%
3 Year Change
-96.39%
5 Year Change
-98.95%
10 Year Change
-99.16%
Max Change
-99.16%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Medical Devices
Description:
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Latest Videos
Apps
Top Articles
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
